by adminTorusBrand | Jul 20, 2017 | Axim Biotechnologies, Press Releases
AXIM Biotechnologies, Inc. (AXIM Biotech) AXIM, +2.42% a world leader in cannabinoid research and development, today announced that it has entered into a Services Agreement with an Israel-based contract research organization (CRO) to begin a clinical proof of concept...
by adminTorusBrand | Jun 27, 2017 | Axim Biotechnologies, Press Releases
NEW YORK, June 27, 2017 — Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC: AXIM), a world leader in...
by adminTorusBrand | Jun 26, 2017 | Axim Biotechnologies, Press Releases
NEW YORK, June 26, 2017 — Medical Marijuana, Inc. (OTC:MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC QB:AXIM), a world leader in...
by adminTorusBrand | Jun 23, 2017 | Axim Biotechnologies, Company News
[vc_row][vc_column][vc_column_text]The newly filed patent involves a novel chewing gum composition developed for the controlled release of cannabinoids and opioid agonists and/or antagonists for treatment of addiction and dependance. The chewing gum also has potential...
by adminTorusBrand | May 4, 2017 | Axim Biotechnologies, Company News
AXIM® Biotechnologies is moving forward with the development of MedChew Rx® pharmaceutical chewing gum products, which are intended as a treatment of multiple sclerosis (MS) symptoms. The company’s product development partner Quay Pharmaceuticals Ltd. has obtained the...
